Cargando…

The Burden of Cardiovascular Disease Attributable to Modifiable Risk Factors and Cost-effectiveness Analysis of IraPEN Program in the General Population of Iran

Background: Cardiovascular diseases (CVDs) contribute to over 30% of deaths worldwide and more than 40% in Iran in 2019. Establishing a cost-effective program to control cardiovascular diseases is essential for any country. This study aimed to estimate the cost-effectiveness of the primary preventio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mokhtari, Mehdi, Khalil, Davood, Farzadfar, Farshad, Daroudi, Rajabali, Asadi-Lari, Mohsen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iran University of Medical Sciences 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448466/ https://www.ncbi.nlm.nih.gov/pubmed/36128278 http://dx.doi.org/10.47176/mjiri.36.73

Ejemplares similares

A cost-effectiveness analysis of risk-based intervention for prevention of cardiovascular diseases in IraPEN program: A modeling study
por: Jamshidi, Amirparviz, et al.
Publicado: (2023)

Timely referral to health centers for the prevention of cardiovascular diseases: IraPEN national program
por: Hadavandsiri, Fatemeh, et al.
Publicado: (2023)

Agreement between Framingham, IraPEN and non-laboratory WHO-EMR risk score calculators for cardiovascular risk prediction in a large Iranian population
por: Mirzaei, Mohsen, et al.
Publicado: (2020)

Prevalence of metabolic syndrome and its determinants among Iranian adults: evidence of IraPEN survey on a bi-ethnic population
por: Jahangiry, Leila, et al.
Publicado: (2019)

Gender and urban–rural residency based differences in the prevalence of type-2 diabetes mellitus and its determinants among adults in Naghadeh: Results of IraPEN survey
por: Ghassab-Abdollahi, Nafiseh, et al.
Publicado: (2023)

Prevalence and Burden of Refractive Errors at National and Sub-national Levels in Iran
por: Mohammadi, Seyed, et al.
Publicado: (2022)

Application of discrete choice experiments to estimate value of life: a national study protocol in Iran
por: Mirzaee, Negar, et al.
Publicado: (2021)

Direct Costs of Hypertension Treatment in Iran
por: Zamandi, Mahmoud, et al.
Publicado: (2023)

Utilization Trend of Parenteral Antidiabetic Drugs in Type 2 Diabetic Patients Covered by Iran Health Insurance Organization from 2011 to 2030
por: Shojaee, Ali, et al.
Publicado: (2023)

The Economic Burden of Breast Cancer in Iran
por: DAROUDI, Rajabali, et al.
Publicado: (2015)

Direct and indirect medical costs of bladder cancer in Iran
por: Raadabadi, Mehdi, et al.
Publicado: (2023)

The incremental cost of implementing the world health organization Package of essential non-communicable (PEN) diseases interventions in Iran
por: Azmin, Mehrdad, et al.
Publicado: (2023)

Trends of national and sub-national burden attributed to kidney dysfunction risk factor in Iran: 1990-2019
por: Nejadghaderi, Seyed Aria, et al.
Publicado: (2023)

Economic burden of colorectal cancer in Iran in 2012
por: Vahdatimanesh, Zahra, et al.
Publicado: (2017)

Metabolic risk factors attributed burden in Iran at national and subnational levels, 1990 to 2019
por: Moradi, Soroush, et al.
Publicado: (2023)

Cost-utility analysis of Cryoballoon ablation versus Radiofrequency ablation in the treatment of paroxysmal atrial fibrillation in Iran
por: Darvishi, Ali, et al.
Publicado: (2022)

Sarcopenia screening strategies in older people: a cost effectiveness analysis in Iran
por: Darvishi, Ali, et al.
Publicado: (2021)

Epidemiology and Hospitalization Cost of Bladder Cancer in Kerman Province, Southeastern Iran
por: RASHIDIAN, Hamideh, et al.
Publicado: (2018)

Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds
por: Daroudi, Rajabali, et al.
Publicado: (2021)

Extent, nature and hospital costs of fireworks-related injuries during the Wednesday Eve Festival in Iran
por: Alinia, Siros, et al.
Publicado: (2013)

Estimation of Generalized Impact Fraction and Population Attributable Fraction of Hypertension Based on JNC-IV and 2017 ACC/AHA Guidelines for Cardiovascular Diseases Using Parametric G-Formula: Tehran Lipid and Glucose Study (TLGS)
por: Saatchi, Mohammad, et al.
Publicado: (2020)

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model
por: Darvishi, Ali, et al.
Publicado: (2023)

National, sub-national, and risk-attributed burden of thyroid cancer in Iran from 1990 to 2019
por: Azangou-Khyavy, Mohammadreza, et al.
Publicado: (2022)

Health-related quality of life among adult patients with visual impairments in Yazd, Iran
por: Raadabadi, Mehdi, et al.
Publicado: (2022)

Direct costs of common osteoporotic fractures (Hip, Vertebral and Forearm) in Iran
por: Rajabi, Marziyeh, et al.
Publicado: (2021)

Estimating the Prevalence of Bladder Cancer by Stage in Iran as a Developing Country
por: Rashidian, Hamideh, et al.
Publicado: (2022)

National geographical pattern of COVID-19 hospitalization, case fatalities, and associated factors in patients covered by Iran Health Insurance Organization
por: Damiri, Soheila, et al.
Publicado: (2022)

Life and health satisfaction in the adult population of Iran
por: Daroudi, Rajabali, et al.
Publicado: (2016)

Development of attributes and levels of mental health insurance services using a discrete choice experiment
por: Rahmani, Hojjat, et al.
Publicado: (2023)

Cost-Effectiveness of Different Cervical Screening Strategies in Islamic Republic of Iran: A Middle-Income Country with a Low Incidence Rate of Cervical Cancer
por: Nahvijou, Azin, et al.
Publicado: (2016)

Public Preferences and Willingness to Pay for a COVID-19 Vaccine in Iran: A Discrete Choice Experiment
por: Darrudi, Alireza, et al.
Publicado: (2022)

Insulin pen use and diabetes treatment goals: A study from Iran STEPS 2016 survey
por: Ebrahimi, Hedyeh, et al.
Publicado: (2019)

Mothers’ preferences and willingness-to-pay for human papillomavirus vaccines in Iran: A discrete choice experiment study
por: Sargazi, Nasrin, et al.
Publicado: (2021)

Ira
por: Petsko, Gregory A
Publicado: (2003)

Cost-effectiveness of a population-based AAA screening program for men over 65 years old in Iran
por: Daroudi, Rajabali, et al.
Publicado: (2021)

Hepatocellular carcinoma incidence at national and provincial levels in Iran from 2000 to 2016: A meta-regression analysis
por: Fattahi, Nima, et al.
Publicado: (2021)

Determinants of healthcare expenditures in Iran: evidence from a time series analysis
por: Rezaei, Satar, et al.
Publicado: (2016)

Health-related quality of life measured using the EQ-5D–5 L: population norms for the capital of Iran
por: Emrani, Zahra, et al.
Publicado: (2020)

Correction to: Health-related quality of life measured using the EQ-5D-5 L: population norms for the capital of Iran
por: Emrani, Zahra, et al.
Publicado: (2020)

Comment on: Estimating Economic Burden of Cancer Deaths Attributable to Smoking in Iran in 2012
por: Geravandi, Sara, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rfk36pabqjdvvq0ehtha7u2a21